{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T08:29:10Z","timestamp":1793521750149,"version":"4.5.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["annallergy.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma & Immunology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.anai.2026.05.019","type":"journal-article","created":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T15:14:59Z","timestamp":1779549299000},"page":"320-328","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Improved asthma outcomes with dupilumab plus medium-dose inhaled corticosteroids vs placebo plus high-dose inhaled corticosteroids"],"prefix":"10.1016","volume":"137","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2591-4696","authenticated-orcid":false,"given":"William W.","family":"Busse","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Njira L.","family":"Lugogo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M.","family":"O\u2019Byrne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard B.","family":"Bacharier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changming","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Ledanois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mena","family":"Soliman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.anai.2026.05.019_bib0001","unstructured":"Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. Accessed May 11, 2026. Available at: https:\/\/ginasthma.org\/2026-gina-strategy-report\/"},{"issue":"1","key":"10.1016\/j.anai.2026.05.019_bib0002","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01147-2019","article-title":"Oral steroid-sparing effect of high-dose inhaled corticosteroids in asthma","volume":"55","author":"Maijers","year":"2020","journal-title":"Eur Respir J"},{"issue":"12","key":"10.1016\/j.anai.2026.05.019_bib0003","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1164\/rccm.201810-1868CI","article-title":"Inhaled corticosteroid therapy in adult asthma. Time for a new therapeutic dose terminology","volume":"199","author":"Beasley","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.anai.2026.05.019_bib0004","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s12020-018-1588-2","article-title":"Glucocorticoid-induced osteoporosis: an update","volume":"61","author":"Compston","year":"2018","journal-title":"Endocrine"},{"issue":"7307","key":"10.1016\/j.anai.2026.05.019_bib0005","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1136\/bmj.323.7307.253","article-title":"Dose-response relation of inhaled fluticasone propionate in adolescents and adults with asthma: meta-analysis","volume":"323","author":"Holt","year":"2001","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.anai.2026.05.019_bib0006","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.jaip.2022.10.040","article-title":"Effect of stepping up to high-dose inhaled corticosteroids in patients with Asthma: UK Database Study","volume":"11","author":"Pavord","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"8","key":"10.1016\/j.anai.2026.05.019_bib0007","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1164\/rccm.200401-033OC","article-title":"Can guideline-defined asthma control be achieved? the Gaining Optimal Asthma ControL study","volume":"170","author":"Bateman","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.anai.2026.05.019_bib0008","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.anai.2019.04.018","article-title":"Global Initiative for Asthma 2016-derived asthma control with fluticasone propionate and salmeterol: a Gaining Optimal Asthma ControL [GOAL] study reanalysis","volume":"123","author":"Bateman","year":"2019","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"4","key":"10.1016\/j.anai.2026.05.019_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2021.100528","article-title":"\u201cReal-life\u201d management of patients with severe asthma in the biologics era: can we do better?","volume":"14","author":"Charriot","year":"2021","journal-title":"World Allergy Organ J"},{"issue":"2","key":"10.1016\/j.anai.2026.05.019_bib0010","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.jaip.2019.08.024","article-title":"Trends and disparities in asthma biologic use in the United States","volume":"8","author":"Inselman","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"12","key":"10.1016\/j.anai.2026.05.019_bib0011","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1080\/02770903.2021.2010749","article-title":"Asthma biologic trial eligibility and real-world outcomes in the United States","volume":"59","author":"Lam","year":"2022","journal-title":"J Asthma"},{"issue":"1","key":"10.1016\/j.anai.2026.05.019_bib0012","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nrd4624","article-title":"Targeting key proximal drivers of type 2 inflammation in disease","volume":"15","author":"Gandhi","year":"2016","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"10.1016\/j.anai.2026.05.019_bib0013","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1080\/1744666X.2017.1298443","article-title":"Commonality of the IL-4\/IL-13 pathway in atopic diseases","volume":"13","author":"Gandhi","year":"2017","journal-title":"Expert Rev Clin Immunol"},{"issue":"14","key":"10.1016\/j.anai.2026.05.019_bib0014","doi-asserted-by":"crossref","first-page":"5147","DOI":"10.1073\/pnas.1323896111","article-title":"Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes","volume":"111","author":"Macdonald","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"14","key":"10.1016\/j.anai.2026.05.019_bib0015","doi-asserted-by":"crossref","first-page":"5153","DOI":"10.1073\/pnas.1324022111","article-title":"Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice","volume":"111","author":"Murphy","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"10.1016\/j.anai.2026.05.019_bib0016","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/all.14151","article-title":"Dual blockade of IL\u20134 and IL-13 with dupilumab, an IL-4R\u03b1 antibody, is required to broadly inhibit type 2 inflammation","volume":"75","author":"Le Floc\u2019h","year":"2020","journal-title":"Allergy"},{"issue":"26","key":"10.1016\/j.anai.2026.05.019_bib0017","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.anai.2026.05.019_bib0018","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1513\/AnnalsATS.201901-071OC","article-title":"Placebo effects in clinical trials evaluating patients with uncontrolled persistent asthma","volume":"16","author":"Luc","year":"2019","journal-title":"Ann Am Thorac Soc"},{"issue":"4","key":"10.1016\/j.anai.2026.05.019_bib0019","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1034\/j.1399-3003.1999.14d29.x","article-title":"Development and validation of a questionnaire to measure asthma control","volume":"14","author":"Juniper","year":"1999","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.anai.2026.05.019_bib0020","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.03393-2020","article-title":"Understanding the key issues in the treatment of uncontrolled persistent asthma with type 2 inflammation","volume":"58","author":"Busse","year":"2021","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.anai.2026.05.019_bib0021","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/all.14611","article-title":"Dupilumab is effective in type 2-high asthma patients receiving high-dose inhaled corticosteroids at baseline","volume":"76","author":"Bourdin","year":"2021","journal-title":"Allergy"},{"key":"10.1016\/j.anai.2026.05.019_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2022.106938","article-title":"Dupilumab efficacy in subgroups of type 2 asthma with high-dose inhaled corticosteroids at baseline","volume":"202","author":"Bourdin","year":"2022","journal-title":"Respir Med"},{"issue":"11","key":"10.1016\/j.anai.2026.05.019_bib0023","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1111\/all.15792","article-title":"Dupilumab sustains efficacy in patients with moderate-to-severe type 2 asthma regardless of inhaled corticosteroids dose","volume":"78","author":"Pavord","year":"2023","journal-title":"Allergy"},{"issue":"12","key":"10.1016\/j.anai.2026.05.019_bib0024","doi-asserted-by":"crossref","first-page":"3303","DOI":"10.1016\/j.jaip.2024.08.038","article-title":"Dupilumab efficacy in children with type 2 asthma receiving high\/medium-dose ICS (VOYAGE)","volume":"12","author":"Maspero","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"10423","key":"10.1016\/j.anai.2026.05.019_bib0025","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0140-6736(23)02284-5","article-title":"Reduction of daily maintenance inhaled corticosteroids in patients with severe eosinophilic asthma treated with benralizumab (SHAMAL): a randomised, multicentre, open-label, phase 4 study","volume":"403","author":"Jackson","year":"2024","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.anai.2026.05.019_bib0026","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1016\/j.jaip.2022.05.019","article-title":"Effect of dupilumab on blood eosinophil counts in patients with asthma, chronic rhinosinusitis with nasal polyps, atopic dermatitis, or eosinophilic esophagitis","volume":"10","author":"Wechsler","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"10","key":"10.1016\/j.anai.2026.05.019_bib0027","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1016\/j.jaip.2022.08.006","article-title":"Dupilumab and eosinophils: a red flag?","volume":"10","author":"Busse","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"8","key":"10.1016\/j.anai.2026.05.019_bib0028","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1164\/rccm.202310-1751LE","article-title":"Biomarkers associated with lung function decline and dupilumab response in patients with asthma","volume":"209","author":"Pavord","year":"2024","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Annals of Allergy, Asthma & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120626002231?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120626002231?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T09:48:38Z","timestamp":1788256118000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1081120626002231"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1081120626002231"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2026.05.019","relation":{},"ISSN":["1081-1206"],"issn-type":[{"value":"1081-1206","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Improved asthma outcomes with dupilumab plus medium-dose inhaled corticosteroids vs placebo plus high-dose inhaled corticosteroids","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2026.05.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}